Discription Flaraxin

Discription Flaraxin

Flaraxin discription.pdf View Download

III-rd and IV stage of malignant neoplasm treatment

Is it possible to bring the disease into absolute remission?

FLARAXIN (F.) is a non-toxic anti-tumoral phytopreparation, interferon gene, stimulating tumoral necrosis factor, destroys tumoral tissue. Immunomodulator and antioxidant. Prevents metastatic spreading and relapse.

Therapeutic peculiarities with Flaraxin. are:
* Excellent endurability of the preparation;
* Absence of collateral phenomena under high anti-tumoral activity;
* High possibility to bring the tumor into full remission;
* Prevention of disease relapse and metastasis spreading prophylactics;
* Absence of toxic manifestations, which is explained by F. high constituency.

Flaraxin. can be used by the patients
* having chemo- or radiotherapy (F. is combined with Polychemotherapy (PCT) and X-ray therapy) ;
* with inoperable form of the disease;
* not subjected to radial therapy;
* with expressed allergic reaction on administration of chemotherapeutic preparations;
* weakened;

Pharmacologic activity of Flaraxin
* Able to connect and blocking the oncological proteins, causing their death;
* Increases the number of natural killers (NK-cells) T-lymphocites;
* Stimulates endogenic interferon and tumor necrosis factor production;
* Normalize immunological background (removes immune violations);
* Normalizes correlations of immune cells CD4/CD8 (helpers-suppressors);

Flaraxin. is effective under:

1) Cerebrum (Brain) cancer (glioma, ependymoma, oligodendroglioma, nervinoma etc.);

2) Skin cancer (melanoma, melanoblastoma, etc.);

3) Lung cancer;

4) Breast cancer;

5) Stomach cancer;

6) Bladder cancer;

7) Colorectal cancer;

8) Colon cancer;

9) Female sexual sphere cancer (uterus, cervix, ovarium);

10) Prostate cancer (adenoma);

11) Mediastinal cancer;

12) Under non-malignant neoplasm of various locality.

13) Flaraxin efficiency in different cases with cancer.

Clinical application of Flaraxin. is advisable in the following cases:
1) F. is advisable to use in patients with pretumoral proliferative processes as well as in patients with minimal tumoral process, after radical surgical treatment when it is necessary to lead reconstruction of anti-tumoral resistance of organism and its homeostatic mechanisms;
2) Treatment with F. can be either basic or background, precede polychemotherapy and radiotherapy, besides it can be used in intervals between treatment cycles as well as the preparation for attained results stability, in the process of classical anti-tumoral therapy. It is stipulated for its minimal toxic effect and influence choice on tumor tissue.
3) In patients with spread tumoral process it is advisable to use F. in complex polychemotherapy, radiotherapy, using its specific anti-tumoral activity and protective properties.
4) Under inability to conduct chemo- and radial therapy F. is used independently.
According to its chemical properties F. is compatible with many anti-tumoral remedies excluding metal-containing, as it has abilities to complex-formation.

If included into treatment scheme Flaraxin. reducing:
* Cardiotoxicity, specified by lypooxigenesis activation, typical to antibiotics of antracyclic group;
* Neurotoxicity - like preparations of vinca-class (Vincristin, Vinblastin);
* Pyramidal disorders and syndrome of “orthostatic hypotension” like Fluorouracil;
* Myelotoxic effect and immunodepression - like alkylating preparations, etc.

Flaraxin. should be included into the following treatment schemes of oncologic patients : Known methods of oncological patients treatment (chemotherapeutic, radial, and surgical) is accompanied by powerful immune suppression, which considerably suppresses immune system function, closing vicious circle of tumoral process. [4,8].

Chemotherapy envisages the use of remedies, having a number of reactionally capable groupings, denaturing proteins of not only tumoral, but also normal cells, by which their high toxicity for the organism can be explained. F. conducts with not only tumoral cells, causing their death, in this case it does not influence hematogenesis, organs of breathing, excretory and digestive systems, CNS, skin, etc. Being powerful immunomodulator it does not suppress immune system, but it raises its level of functional activity.

Prescribing F. before chemotherapy it is necessary to take into consideration some of its peculiarities. Under the influence of F. tumoral cells become more vulnerable relative to the factors of natural anti-tumoral immunity and anti-tumoral cytostatics. That is why for more effective treatment with F. it is necessary to have initial immune-biochemical indices of the patient, especially under preparation for chemotherapy.

It is necessary to prescribe F. under low level of natural killers cytostatic activity (lower 40% - by all means, from 50 to 55% - preferably); in presence of initial non-protein SН-groups, in blood serum (spontaneous dysproteinemia with autoimmune aggression); as well as under violation of oxidation-reductive (SH-SS) potential of serum proteins. These violations are often combined with each other

If 8 prescribed injections of F. normalized the violations mentioned above, the chemotherapy can be started. If optimal immune-biochemical indices after 8 injections are not achieved on the background of positive dynamics, it is reasonable to prescribe 8 more injections.

If it is impossible to lead at least one from presented immune-biochemical tests, it is possible to guide on clinical picture of the disease course. Under noted subjective improvement after first 8 injections of F. 8 more injections can be repeated. If some subjective or objective indications are absent, the following injections are not desirable.

It is impossible to continue injections when individual intolerance towards the preparation appears. In such cases it is preferable to insert preparations lowering auto-allergic incite of the organism (cenolog, suprastin, etc.) into the treatment scheme of the patient and to carry out several plasmapheresis displays.

Treatment with F. is better to start immediately after finishing chemotherapy especially if lowering of immune-biochemical indices is revealed. If further reiteration of chemotherapy is supposed the treatment with F. is necessary to continue up to maximal improvement of immune-biochemical indices. One or two courses of F. in this case do not depend on the level of effectiveness, but on what biochemical indices are set after chemotherapy.

Cancer is an immunological problem related with violation of antibodies formation as a responce to complex antigens of onco-associated proteins and remedies [8,13]. If immune-biochemical indices are evidently reduced than in this case the use of Plasmapheresis is an important addition to medical therapy. Also application of plasmapheresis is desirable after multiple courses of Poly-Chemotherapy (PCT). In this case the most informative to us is the definition of initial non-protein SН-groups in blood serum. Their appearance is an evidence of Plasmapheresis necessity prescription. The use of F. between the courses of chemotherapy can replace the function of plasmapheresis. The application of F. between the courses of Chemotherapy can replace the function of Plasmapheresis, because F. has ability to have connection with immune complexes.

If after the mutual application of Chemotherapy and Flaraxin (F.) negative immune-biochemical indices appear (especially SH-groups) than the application of plasmapheresis is necessary. The number of Plasmapheresis corses can vary depending on the level of immune system violations (the control is the disappearance of SH-groups). So, for instance, under fractional plasmapheresis it is necessary to apply from 5 till 10 courses (with cleaning during each course up to 500 ml of blood).

The prescription of F. strengthens chemotherapeutic effect and if endurance of the chemo-preparations applied is good, than reduction of its concentration is not desirable.

Combination of F. and chemo- preparations in reduced doses is preferable in patients with accompanied diseases making massive chemotherapy application difficult. In heavy patients who got the prescription of F. it is necessary to reduce dose of chemo-preparations (1/5-1/10 of the normal dose) into the treatment scheme with the aim to strengthen oncologic activity of Flaraxin and also desirable to prescribe chemo-preparation that has never been used in this patient.
The term of mutual application of F. and chemo-preparations must be defined by clinical picture and immune-biochemical indices of the patient. If each of these courses is accompanied by normalization of immune-biochemical indices, it is necessary to continue combination of Poly-Chemotherapy and F. 3-4 courses of F. can be considered as the ideal scheme, amplifying Chemotherapy and 1-2 courses of F. more in the following year after the end of Chemotherapy. It is also advisable to prescribe F. during the dispensary observation under disclosure of risk factors (stresses, reduction of immune-biochemical indices etc.)
In the intervals between Chemotherapy when it is impossible to use F., phitopreparations of FITOMAX group are prescribed. Their mutual application is justified in these cases, when the application of the 1-st massive chemotherapy course is supposed.

It was noted, that the use of preparations containing vegetative polyphenols and biological supplements with increased content of bio-flavonoids (silybrum mariarum, hellebores caucasicus, viola tricolor etc.) cause negative influence on therapeutic effect of F. (the studies are present). Probably in this case the level of Polyphenols chemical reaction with other components are playing main role (for instance, glychosylation).

Clinically proved high efficiency of F. application in preoperative period. First of all, some decrease of tumoral nods is marked, which essentially simplifies the technique of operative intrusion; second, its powerful immunomodulatory and interferogenic properties allow to carry out surgical intrusion on good immunological background. Thus, the method of surgical treatment with preliminary application of 1-2 courses of F. therapy is clinically justified..

Accounting high anti-metastatic activity of F., it is advisable to carry out the treatment in post-operative period (1-2 courses of F.) as well as before application of chemotherapeutic preparations.

In the cases when the use of chemotherapeutic preparations do not give positive results the application of F. is prescribed and able to give positive results.

Clinically proved positive influence of F. on the patients: F improves general state; Tumoral nods became smaller or disappearing at all; F gives improvements to immunological indexes of immune system; F. increases vitality and movement activity; Reduces pain.

Take in to account possibility of Support from our medical staff on cancer treatment with Flaraxin and additional treatment recommendations.

The efficiency of the Flaraxin is confirmed by:

Kiev Medical Institute Department of Oncology,

R.E.Kavetskyi Institute of Experimental Pathology, Oncology and Radio-biology
of National Academy of Science of Ukraine

Filatov Institute of eye diseases and tissue therapy AMS of Ukraine,
Department of Oncology of Crimean State Medical University named after S.I.Georgiyevsky,
Department of Oncology

D. K. Zabolotny Institute of Microbiology and Virology of NAS of Ukraine.

Stccc Phoenix is looking for doctors and medical centers around the world to work together ,to bring cancer into absolute remission ?
You can contact us: Contact information